FcγRIIB-specific antibodies and methods of use thereof

Details FcγRIIB-specific antibodies and methods of use thereof FcγRIIB-specific antibodies and methods of use thereof

2003-08-14

2008-09-16

Haddad, Maher M. (Department: 1644)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

Blood proteins or globulins, e.g., proteoglycans, platelet...

C530S387300, C530S388100, C530S388200, C530S391100, C424S130100, C424S133100, C424S134100, C424S136100

Reexamination Certificate

active

07425620

ABSTRACT:
The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.

REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 5648260 (1997-07-01), Winter et al.
patent: 5711944 (1998-01-01), Gilbert et al.
patent: 5837243 (1998-11-01), Deo et al.
patent: 5888533 (1999-03-01), Dunn
patent: 5945115 (1999-08-01), Dunn et al.
patent: 6019968 (2000-02-01), Platz et al.
patent: 6132764 (2000-10-01), Li et al.
patent: 6194551 (2001-02-01), Idusogie et al.
patent: 6218149 (2001-04-01), Morrison et al.
patent: 6339069 (2002-01-01), Meers et al.
patent: 6420149 (2002-07-01), Fukuda et al.
patent: 6472511 (2002-10-01), Leung et al.
patent: 6528624 (2003-03-01), Idusogie et al.
patent: 6737056 (2004-05-01), Presta
patent: 2001/0036459 (2001-11-01), Ravetch
patent: 2002/0028486 (2002-03-01), Morrison et al.
patent: 2003/0115614 (2003-06-01), Kanda et al.
patent: 2004/0002587 (2004-01-01), Watkins et al.
patent: 2004/0185045 (2004-09-01), Koenig et al.
patent: 2005/0037000 (2005-02-01), Stavenhagen et al.
patent: 2005/0064514 (2005-03-01), Stavenhagen et al.
patent: 2005/0215767 (2005-09-01), Koenig et al.
patent: 2005/0260213 (2005-11-01), Koenig et al.
patent: 2006/0013810 (2006-01-01), Johnson et al.
patent: 2006/0073142 (2006-04-01), Chan et al.
patent: 2006/0177439 (2006-08-01), Koenig et al.
patent: 2007/0253948 (2007-11-01), Chan et al.
patent: 0 332 865 (1989-09-01), None
patent: 0 629 703 (1994-12-01), None
patent: 0 359 096 (1997-11-01), None
patent: 0 953 639 (1999-11-01), None
patent: 1 006 183 (2000-06-01), None
patent: 0 343 950 (2000-10-01), None
patent: WO 94/18330 (1994-08-01), None
patent: WO 99/19362 (1999-04-01), None
patent: WO 99/41285 (1999-08-01), None
patent: WO 99/58572 (1999-11-01), None
patent: WO 00/42072 (2000-07-01), None
patent: WO 01/79299 (2001-10-01), None
patent: WO 03/035835 (2003-05-01), None
patent: WO 03/066095 (2003-08-01), None
patent: WO 2004/016750 (2004-02-01), None
patent: WO 2005/110474 (2005-11-01), None
patent: WO 2005/115452 (2005-12-01), None
patent: WO 2006/066078 (2006-06-01), None
patent: PCT/US2007/072151 (2007-06-01), None
Pluckthun et al. Immunotechnology 1997, 3:83-105.
Abra et al. The next generation of liposome delivery systems: recent experience with tumor-targeted, sterically-stabilized immunoliposomes and active-loading gradients. J Liposome Res. Feb.-May 2002;12(1-2):1-3.
Bendas G, Immunoliposomes: a promising approach to targeting cancer therapy. BioDrugs. 2001;15(4):215-24.
Billadeau et al., ITAMs versus ITIMs: striking a balance during cell regulation, J Clin Invest. Jan. 2002;109(2):161-8.
Bolland and Ravetch. Inhibitory pathways triggered by ITIM-containing receptors. Adv Immunol. 1999;72:149-177.
Bolland et al. Genetic modifiers of systemic lupus erythematosus in FcgammaRIIB(-/-) mice. J Exp Med. May 6, 2002;195(9):1167-74.
Brauweiler et al., Partially Distinct Molecular Mechanisms Mediate Inhibitory FcγRIIB Signaling In Resting and Activated B Cells, Journal of Immunology, 2001, 167: 204-211.
Brown EJ. In vitro assays of phagocytic function of human peripheral blood leukocytes: receptor modulation and signal transduction. Methods Cell Biol. 1994;45:147-164.
Budde et al., Specificity of CD32 mAB for FcγRIIa, FcγRIIb1, and FcγRIIb2 expressed in transfected mouse B cells and BHK-21 cells,Leukocyte Typing V: White Cell Differentiation Antigens. 1995, 828-832. (Schlossman, Boumsell, Gilks, Harlan, Kishomoto, eds.).
Callanan et al., The IgG Fc Receptor, FcγRIIB is a target for deregulation by chromosomal translocation in malignant lymphoma, PNAS, Jan. 2000 97(1): 309-314.
Cameron et al.. Differentiation of the human monocyte cell line, U937, with dibutyryl cyclicAMP induces the expression of the inhibitory Fc receptor, FcgammaRIIb. Immunol Lett. Oct. 1, 2002;83(3):171-9.
Camilleri-Broët et al., FcgammaRIIB is differentially expressed during B cell maturation and in B-cell lymphomas. British Journal of Haematology, 2004; 124:55-62.
Cassard et al., Modulation of tumor growth by inhibitory Fcgamma receptor expressed by human melanoma cells. The Journal of Clinical Investigation, Nov. 2002; 110(10):1549-1557.
Chappel et al., Identification of the FCgamma receptor class I binding site in human IgG through the use of recombinant IgG1/IgG2 hybrid and point-mutated antibodies. Proc. Natl. Acad. Sci., USA, Oct. 1991; 88(20):9036-9040.
Clynes et al. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000 6(4): 443-6.
Damle et al., B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. Blood Jun. 1, 2002; 99(11):4087-4093.
Davies et al. Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII. Biotechnol Bioeng. Aug. 20, 2001;74(4):288-94.
Daëron et al., The Same Tyrosine Based Inhibition Motif, in the Intracytoplasmic Domain of FcγRIIB, regulates Negatively BCR, TCR- and FcR dependent Cell Activation, Immunity, Nov. 3, 1995: 635-646.
Eppstein et al. Biological activity of liposome-encapsulated murine interferon gamma is mediated by a cell membrane receptor. Proc Natl Acad Sci U S A. Jun. 1985;82(11):3688-92.
Fanger et al., Production and Use of Anti-FcR Bispecific Antibodies, Immunomethods 1994, 4: 72-81.
Farag, et al. FcγRIIIa and FcγRIIIa Polymorphisms Do Not Predict Response to Rituximab in B-Cell Chronic Lymphocytic Leukemia. Blood. Oct. 16, 2003.
Fidler, I. J. (1985). “Macrophages and metastasis—a biological approach to cancer therapy.” Cancer Res 45(10): 4714-26.
Gerber et al., Stimulatory and inhibitory signals originating from the macrophage Fcgamma receptors, Microbes Infect. Feb. 2001;3(2):131-9.
Holmes et al. Alleles of the Ly-17 alloantigen define polymorphisms of the murine IgG Fc receptor. Proc Natl Acad Sci U S A Nov. 1985;82(22):7706-10.
Hwang et al. Hepatic uptake and degradation of unilamellar sphingomyelin/cholesterol liposomes: a kinetic study. Proc Natl Acad Sci U S A. Jul. 1980;77(7):4030-4.
Isaacs et al., Therapy with monoclonal antibodies. II. The contribution of Fcgamma receptor binding and the influence of CH1 and CH3 domains on in vivo effector function. The Journal of Immunology, 1998; 161:3862-3869.
Jefferis et al. Recognition sites on human IgG for Fc gamma receptors: the role of glycosylation. Immunol Lett Jan. 1995;44(2-3):111-7.
Kagari et al., Essential Role of Fcgamma Receptors in anti-type II collagen antibody induced arthritis, J. Immunol. Apr. 2003 170: 4318-24.
Lifely et al. Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions. Glycobiology. Dec. 1995;5(8):813-22.
Lin et al. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med. 2001 193(6): 727-739.
Lin et al.. The macropage growth factor CSF-1 in mammary gland development and tumor progression. J Mammary Gland Biol Neoplasia 2002 7(2): 147-62.
Lyden et al. The Fc receptor for IgG expressed in the villus endothelium of human placenta is Fc gamma RIIb2. J Immunol Mar. 15, 2001;166(6):3882-9.
Malbec et al., Fcε Receptor I-Associatedlyn-Dependent Phosphorylation of Fcγ Receptor IIB During Negative Regulation of Mast Cell Activation. J. of Immunology, 1998, 160: 1647-58.
Maruyama K. In vivo targeting by liposomes. Biol Pharm Bull. Jul. 2000;23(7):791-9.
Metcalfe, Mast Cells, Physiol Rev. O

Affiliated with

Also associated with

Rating

FcγRIIB-specific antibodies and methods of use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with FcγRIIB-specific antibodies and methods of use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and FcγRIIB-specific antibodies and methods of use thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3992756